The role of granulocyte colony-stimulating factors in the prevention of neutropenia and febrile neutropenia – the current state of knowledge

• Authors: Marta A. Sobas , Tomasz Wróbel
• Languages of publication: EN

Abstracts

EN

Granulocyte colony-stimulating factors, introduced in the 1990s to prevent neutropenic fever, improve patients’ prognosis after myelotoxic chemotherapy. G-CSFs accelerate bone marrow recovery, shortening the duration of neutropenia and reducing its intensity as well as the risk of febrile neutropenia. There are short- and long-acting G-CSFs available these days. This paper is a review of the efficacy, toxicity and indications for short- and long-acting G-CSFs as indicated in the most recent studies.

Keywords

EN

guidelines; long- and short-acting granulocyte colony-stimulating factors; neutropenia; neutropenic fever; review

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OncoReview
• Year: 2017
• Volume: 7
• Issue: 1
• Pages: 15-21

Contributors

author

Marta A. Sobas

• Department of Haematology, Blood Cancers and Bone Marrow Transplantation, Wroclaw Medical University, Poland

author

Tomasz Wróbel

• Department of Haematology, Blood Cancers and Bone Marrow Transplantation, Wroclaw Medical University, Poland

References

• 1. Klastersky J, de Naurois J, Rolston K et al. Management of febrile neutropenia: ESMO Clinical Practice Guidelines. Ann Oncol 2016; Suppl. 5: v111-v118.
• 2. Aapro MS, Bohlius J, Cameron DA et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 2011; 47(1): 8-32.
• 3. NCCN Clinical Practice Guidelines in Oncology, Myeloid Growth Factors, Version 2.2016.
• 4. Smith TJ, Bohlke K, Lyman GH et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015; 33(28): 3199-3212.
• 5. Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MA SCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer 2013; 21(5): 1487-1495.
• 6. Pettengell R, Schwenkglenks M, Leonard R et al. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INCEU prospective observational European neutropenia study. Support Care Cancer 2008; 16(11): 1299-1309.
• 7. Bosly A, Bron D, Van Hoof A et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol 2008; 87(4): 277-283.
• 8. Kaushansky K. Lineage-specific hematopoietic growth factor. N Engl J Med 2006; 354(19): 2034-2045.
• 9. Crawford J, Ozer H, Stoller R et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991; 325(3): 164-170.
• 10. Holmes FA, Jones SE, O’Shaughnessy J et al. Comparable efficacy and safety of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy- induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 2002; 13: 903-909.
• 11. Green M, Koelbl H, Baselga J et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14: 29-35.
• 12. Mitchell A, Li X, Woods M et al. Comparative effectiveness of granulocyte colony-stimulation factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. J Oncol Pharm Pract 2016; 22(5): 702-716.
• 13. Wang L, Baser O, Kutikova L et al. The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2015; 23(11): 3131-3140.
• 14. Mhaskar R, Clark OA , Lyman G et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database Syst Rev 2014; (10): CD003039.
• 15. Kim MG, Han N, Lee E et al. Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis. Bone Marrow Transplant 2015; 50(4): 523-530.
• 16. Gerds A, Fox-Geiman M, Dawravoo K et al. Randomized phase III trial of pegfilgrastim versus filgrastim after autologus peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2010; 16(5): 678-685.
• 17. Frączak E, Dybko J, Rybka J et al. The effect of lipegfilgrastim in hematopoietic reconstitution and supportive treatment after megachemotherapy with autologous peripheral blood stem cell transplantation in patients with lymphoproliferative malignancies. OncoReview 2016; 6(2): 66-71.
• 18. Link H, Nietsch J, Kerkmann M et al. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy – representative sample survey in Germany. Support Care Cancer 2016; 24(1): 367-376.
• 19. Lugtenburg P, Silvestre AS, Rossi FG et al. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens. Clin Lymphoma Myeloma Leuk 2012; 12(5): 297-305.
• 20. Cesaro S, Nesi F, Tridello G et al. A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. PloS One 2012; 5: 713-720.
• 21. Lyman GH, Reiner M, Morrow PK et al. The effect of filgrastim or pegfilgrastim on survival outcomes of patients with cancer receiving myelosuppresive chemotherapy. Ann Oncol 2015; 26(7): 1452-1458.
• 22. Drullinsky P, Sugarman SM, Fornier MN et al. Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clin Breast Cancer 2010; 10(6): 440-444.
• 23. Chatta GS, Price TH, Allen RC et al. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood 1994; 84(9): 2923-2929.
• 24. Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 1996; 88(1): 335-340.
• 25. Cooper KL, Madan J, Whyte S et al. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 2011; 11: 404.
• 26. Hershman DL, Wilde ET, Wright JD et al. Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol 2012; 30(8): 806-812.
• 27. Lyman GH, Dale DC, Wolff DA et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28(17): 2914-2924.

• Document Type: article